In the 2025 syringe residue analysis study, the share of the synthetic cathinone alpha-PVP increased to 30% of all analysed syringes (2024: 23%). At the same time, the share of amphetamine decreased to 16% (2024: 20%). Buprenorphine remained the most detected substance used by injection (44%).
The ranking of the three most common substances remained the same as in 2024: buprenorphine, alpha-PVP and amphetamine. The change is particularly visible in the increase in the share of alpha-PVP and the decrease in the share of amphetamine.
The data are based on the syringe residue analysis study, in which used syringes returned to health counselling centres in Helsinki are analysed. The method produces laboratory-verified data on substances used by injection and changes over time.
- Buprenorphine has remained the most used substance by injection (44% in 2025).
- The share of alpha-PVP increased to 30% and clearly surpassed amphetamine.
- Cocaine is rarely used by injection (2.6%), despite an increase in use at the population level.
The situation in Helsinki in 2025
The 2025 collection was carried out at social and health counselling centres in Helsinki. Buprenorphine remained clearly the most common finding. Of all buprenorphine detected, 44% originated from the buprenorphine–naloxone combination product (Suboxone).
Alpha-PVP was the second most common substance, and its share continued to increase. Its use was clearly less common in eastern parts of Helsinki than in areas closer to the city centre. Injecting use of amphetamine continued to decline relative to the other most common substances.
Among benzodiazepines, alprazolam (e.g. Ksalol, Xanor) was clearly the most common (15%). Cocaine was detected in 2.6% of syringes. Although cocaine use has increased at the population level, injecting use remains limited compared to the most common substances.
| Substance | 2025 |
|---|---|
| Buprenorphine | 44,8 |
| Alpha-PVP | 29,9 |
| Naloxone | 19,5 |
| Amphetamine | 15,6 |
| Alprazolam | 14,9 |
| Methadone | 3,9 |
| Cocaine (BE) | 2,6 |
| MDMA | 1,3 |
| Testosterone | 0,6 |
| Olanzapine | 0,6 |
| Biperiden | 0,6 |
| Methylphenidate | 0,6 |
| Diazepam | 0,6 |
| Gabapentin | 0,6 |
| Methamphetamine | 0,6 |
| Bupropion | 0,6 |
| Tramadol | 0,6 |
| Midazolam | 0,6 |
The syringe residue analysis study has been conducted in Finland since 2017. Monitoring data show that there have been long-term changes in the prevalence of substances used by injection.
Buprenorphine and amphetamine have been key substances throughout the observation period, but in recent years the share of synthetic cathinones, particularly alpha-PVP, has increased. Findings of more than one substance are identified annually in some syringes, indicating combined use of substances and repeated use of the same syringe.
Heroin or fentanyl have not been detected in syringes in recent years.
The situation in Finland differs from many European countries
Finland participates in the study as part of the European ESCAPE network. A harmonised study design enables comparisons between European cities.
In Western and Central Europe, heroin and cocaine are typically the most common substances used by injection. In Finland, injecting use is focused on buprenorphine, amphetamine and, in recent years, synthetic cathinones. There are significant differences between countries in the substances used intravenously.
Source
Syringe residue analysis study (ESCAPE)
Description of the statistics
In the syringe residue analysis study, randomly selected used syringes and needles returned to health counselling centres are analysed. The aim is to obtain a sample that is as representative as possible of injecting drug use. Analyses are conducted using highly sensitive chromatographic–mass spectrometric methods at THL’s forensic toxicology laboratory.
The study produces objective data on the prevalence of substances used by injection and changes over time. The collection is anonymous, and no personal data are collected.
Update schedule
The data are updated annually after the completion of each collection and analysis period.
Contact details
Lead Specialist
tel. +358 29 524 8425
[email protected]